Tykerb lapatinib regulatory update

GlaxoSmithKline submitted an sNDA to FDA for Tykerb lapatinib to treat inflammatory breast cancer. The HER1 and HER2 receptor kinase inhibitor is approved in the U.S. for use in combination with cap...